Stock Price

A junior explorer just raised millions to follow up on a stunning 2013 gold find. Is it a long shot, or a savvy play on Saskatchewan's resource boom?

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

As AI and crypto converge, a new project bets its future not on speculation, but on tangible utility and verifiable security. We deconstruct the model.

Canada's new 'AI for All' strategy bets billions on sovereign compute and closing its adoption gap. Can this ambitious plan build a uniquely Canadian AI future?

The S&P/TSX Composite's latest rebalance is more than a market footnote. It's a story of rising commodity players and struggling consumer-facing firms.

AM Best affirms Victoria Insurance's 'Good' rating despite a shrinking footprint, revealing a high-stakes balancing act between a fortress balance sheet and immense market risks.

Set to join the Russell 3000, Starfighters Space and its unique F-104 fleet bring Wall Street's focus to a new class of aerospace infrastructure.

As Florida celebrates National Homeownership Month, the dream of owning a home clashes with a perfect storm of insurance crises and affordability challenges.

Tuniu extends its non-GAAP profit streak to five quarters, revealing a strategy where aggressive cost control and market tailwinds forge a path to stability.

Ninety percent of firms have increased AI marketing investment, yet a new report reveals only 12% can prove it works. This is the story of a growing crisis.

Sunshine Silver's successful IPO is more than a financial event; it's a high-stakes bet on reviving a storied mine and securing America's silver supply.

Struggling biotech Tempest Therapeutics adds finance and medical heavyweights to its board. Is this a strategic reset or a last-ditch effort to survive?

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

As NEXGEL prepares for a key investor conference, it faces a crucial test: convincing the market its advanced hydrogel tech can overcome recent financial hurdles.

Teva's new Eylea biosimilar hits Europe, a key move in its 'Pivot to Growth' strategy that promises to shake up the lucrative ophthalmology market.

With record device sales providing a solid financial base, RenovoRx nears a critical milestone in its high-stakes Phase III trial for a new pancreatic cancer therapy.

Vivakor's new $108M crude oil deal aims to merge trading with infrastructure, but market volatility and a challenging financial backdrop test its ambitious strategy.

Manufactured Housing Properties Inc. is raising $100M to expand in the Sun Belt. Is this niche real estate play the answer to the affordability crisis?

Canaccord Genuity posts record profits and hikes its dividend, but behind the stellar numbers lies a crucial strategic review of its valuable UK business.

As AI tools offer students instant answers, EdTech firm Thea has served a billion questions instead. We investigate its 'Socratic' model and its ambitious bid to rewire learning.